Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase IIIB, Randomized, Active Controlled Open-Label Study Of Sunitinib (Sutent) 37.5 Mg Daily Vs Imatinib Mesylate 800 Mg Daily In The Treatment Of Patients With Gastrointestinal Stromal Tumors (GIST) Who Have Had Progressive Disease While On 400 Mg Daily Of Imatinib

NCT00372567 is registered in ClinicalTrials.gov with Pfizer as lead sponsor.

NCT NCT00372567
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00372567 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase IIIB, Randomized, Active Controlled Open-Label Study Of Sunitinib (Sutent) 37.5 Mg Daily Vs Imatinib Mesylate 800 Mg Daily In The Treatment Of Patients With Gastrointestinal Stromal Tumors (GIST) Who Have Had Progressive Disease While On 400 Mg Daily Of Imatinib
Lead sponsor
Pfizer
Phase
Phase 3
Overall status
Terminated
Start date
June 30, 2007
Completion date
November 30, 2009
Enrollment
69 (actual)
Sites
25

Conditions

As the registry lists them; a condition with its own page is linked.

gastrointestinal stromal tumor